Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Meeting Report
  • Published:

‘Urology: Today's Advances, Tomorrow's Clinical Practice’, Cannes, November 2003

Current Thinking in Prostatic Diseases: insights into dual 5α-reductase inhibitor therapy in BPH and prostate cancer

Prostate Cancer and Prostatic Diseases volume 7, pages 91–92 (2004)Cite this article

The year 2003 was an exciting one in urology with publication of two major studies, MTOPS and PCPT,1,2 the results of which are likely to influence clinical practice in the coming years. The high level of interest in these and other recent data pertinent to the treatment of BPH and the potential for prostate cancer chemoprevention was the springboard for a meeting attended by over 70 urologists from 23 countries. Reported here are key highlights from the meeting.

Data from the recently published Medical Therapy of Prostatic Symptoms (MTOPS) study presented during the meeting demonstrated that monotherapy with doxazosin (α-adrenergic receptor blocker) or finasteride (5α-reductase inhibitor) significantly reduces the overall risk for BPH progression, but that combination therapy is most effective. The data also highlighted that the long-term risk of acute urinary retention and invasive treatment (eg prostatectomy) was significantly reduced by combination therapy or 5α-reductase inhibition, but not by α-adrenergic receptor blockade alone. For the purposes of the study, the primary end point, overall clinical progression was defined as increased symptoms, development of acute urinary retention, renal insufficiency due to BPH (50% or greater rise in a baseline serum creatinine of 1.5 mg/dl or greater), recurrent UTI or urosepsis, and urinary incontinence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  2. Thompson IM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  Google Scholar 

  3. Bartsch G et al. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. Br J Urol 2004; 93: 27–29.

    Article  Google Scholar 

  4. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

  5. Mochtar CA et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695–700.

    Article  CAS  Google Scholar 

  6. Debruyne F, Barkin J, Roehrborn C . Long-term dutasteride therapy results in continued improvements in symptoms and peak urinary flow in men with symptomatic benign prostatic hyperplasia. Abstract 1960, XIXth EAU, Congress, Istanbul, 17–120 March 2004.

  7. Tammela T, Barkin J, Roehrborn C . Long-term dutasteride therapy results in sustained reductions in total prostate volume in men with symptomatic benign prostatic hyperplasia. Abstract 1928, XIXth EAU Congress, Istanbul, 17–20 March 2004.

  8. Thompson IM et al. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003; 44: 650–655.

    Article  CAS  Google Scholar 

  9. Thomas LN et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003; 170: 2019–2025.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mater Misercordiae Hospital, Ireland

    J M Fitzpatrick

Authors
  1. J M Fitzpatrick
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitzpatrick, J. ‘Urology: Today's Advances, Tomorrow's Clinical Practice’, Cannes, November 2003. Prostate Cancer Prostatic Dis 7, 91–92 (2004). https://doi.org/10.1038/sj.pcan.4500724

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500724

Search

Advanced search

Quick links